USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
26 Apr 2022 | 02:45 PM GMT

Virtual Care for Cardiometabolic Diseases: Opportunities for Pharma

Anchored by:

Kevin Darcy
Director, Link Strategy
VEEVA
Jana Goldberg
National Medical Director, VP Clinical
HEARTBEAT HEALTH

Participants:

Jana Goldberg National Medical Director, VP ClinicalHeartbeat Health
Jana Goldberg
National Medical Director, VP ClinicalHeartbeat Health
Kevin Darcy Director, Link StrategyVeeva
Kevin Darcy
Director, Link StrategyVeeva
Amanda Goltz US Lead, Healthcare Startups and VCAWS
Amanda Goltz
US Lead, Healthcare Startups and VCAWS
Bhavesh Vyas Independent ConsultantDOCFLIQ
Bhavesh Vyas
Independent ConsultantDOCFLIQ
Claire Donnelly Head of Medical PartnershipsHappitech
Claire Donnelly
Head of Medical PartnershipsHappitech
Joseph Rubinsztain CEOChronWell
Joseph Rubinsztain
CEOChronWell
Karine Soulat Marketing Consultant on health and e healthKe-Health
Karine Soulat
Marketing Consultant on health and e healthKe-Health
Mathieu Chaffard Digital Health Innovation ManagerRoche Diagnostics
Mathieu Chaffard
Digital Health Innovation ManagerRoche Diagnostics

About this Meeting

Cardiometabolic diseases are a leading cause of death globally, these conditions span from heart failure, stroke, type2 diabetes, hypertension and many others. Better patient outcomes are emerging with the use of Virtual Care programs, therefore there seems to be a huge opportunity for Pharma to work in tandem with Virtual Care companies in order to drive better health outcomes for their patients. But the business model for Pharma is still not clear. 

 Join this discussion which will deep dive into the opportunities for Pharma in the Virtual Care space. If you are working in the area of Cardiometabolic Diseases - this is the meeting for you!   

  •  Drivers for Pharma and Virtual Care companies in the cardiometabolic space to partner up. What are pharma looking for when partnering (e.g. insights from patient data, improved patient engagement with the company, better adherence, etc)?  
  •  What are the most scalable and sustainable business models for Pharma adopting Virtual care solutions in the cardiometabolic space?
  •  What is the ROI for Pharma? 
 Real Examples: AZ and AliveCor, Novartis & Biofourmis, Amgen and Datos, Wellthy and Ferrer, Bayer and Sidekick. Have these been successful? What can we learn from these? Any thoughts?